Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Baxter
Harvard Business School
Dow
McKinsey

Last Updated: January 24, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LAMISIL

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Lamisil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002394 ↗ Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment Completed Novartis N/A 1969-12-31 The purpose of this study is to see if it is safe and effective to give Lamisil to HIV-positive patients with thrush (a fungal infection) that has not responded to fluconazole.
NCT00117767 ↗ Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed Novartis Pharmaceuticals Phase 3 2004-06-01 Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.
NCT00443820 ↗ Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed Novartis Pharmaceuticals Phase 3 2006-12-01 This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
NCT00443898 ↗ Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed Novartis Pharmaceuticals Phase 3 2006-12-01 This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lamisil

Condition Name

Condition Name for Lamisil
Intervention Trials
Onychomycosis 6
Healthy 5
HIV Infections 1
Itraconazole Adverse Reaction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lamisil
Intervention Trials
Onychomycosis 7
Mycoses 1
Infection 1
HIV Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lamisil

Trials by Country

Trials by Country for Lamisil
Location Trials
United States 48
Canada 3
Germany 1
Turkey 1
Iceland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lamisil
Location Trials
Missouri 3
Virginia 3
Texas 3
New York 3
New Jersey 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lamisil

Clinical Trial Phase

Clinical Trial Phase for Lamisil
Clinical Trial Phase Trials
Phase 3 5
Phase 2 2
Phase 1 8
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lamisil
Clinical Trial Phase Trials
Completed 17
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lamisil

Sponsor Name

Sponsor Name for Lamisil
Sponsor Trials
Novartis Pharmaceuticals 3
Novartis 2
Roxane Laboratories 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lamisil
Sponsor Trials
Industry 17
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Boehringer Ingelheim
McKesson
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.